Mylan and Mabion Reach Agreement on Rituximab Biosimilar

According to a Mabion press release, Mylan recently reached a deal with Mabion, a Polish biotech firm, for the exclusive right to commercialize Mabion’s rituximab biosimilar candidate in EU countries and non-EU Balkan states. The deal included an upfront payment of $10 million and additional milestone payments and royalties.  Rituximab is currently marketed in the EU by Roche under the brand name Mabthera®.